Early Prostate Cancer: Hedonic Prices Model of Provider-Patient Interactions and Decisions

International Journal of Radiation Oncology Biology Physics

Volumn 70, Issue 4, 2008, Pages 1158-1168

  Jani, Ashesh B ^a   Hellman, Samuel ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Health economics; Medical decision making; Prostate cancer; Prostatectomy; Radiotherapy

Indexed keywords

BIOMEDICAL ENGINEERING; DECISION MAKING; MEDICAL IMAGING; RADIOTHERAPY;

HEALTH ECONOMICS; MEDICAL DECISION MAKING; PROSTATE CANCERS; PROSTATECTOMY;

TUMORS;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CONTROLLED STUDY; COST BENEFIT ANALYSIS; EXTERNAL BEAM RADIOTHERAPY; GASTROINTESTINAL TRACT FUNCTION; HUMAN; MALE; MEDICAL DECISION MAKING; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; TREATMENT PLANNING; URINARY TRACT FUNCTION;

AGE FACTORS; AGED; CRITICAL PATHWAYS; DATABASES, FACTUAL; DECISION MAKING; ERECTILE DYSFUNCTION; HUMANS; MALE; MIDDLE AGED; MODELS, ECONOMIC; PATIENT SATISFACTION; PHILOSOPHY; PHYSICIAN-PATIENT RELATIONS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECTAL DISEASES; TREATMENT OUTCOME; URETHRAL STRICTURE; URINARY INCONTINENCE;

EID: 39749100129     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2007.07.2349     Document Type: Article

References (49)

1. Jani A.B., and Hellman S. Early prostate cancer: clinical decision-making. Lancet 361 (2003) 1048-1053
2. Jemal A., Murray T., Ward E., et al. Cancer statistics, 2005. CA Cancer J Clin 55 (2005) 10-30
3. Gronberg H. Prostate cancer epidemiology. Lancet 361 (2003) 859-864
4. Hummel S., Paisley S., Morgan A., et al. Clinical and cost-effectiveness of new and emerging technologies for early localised prostate cancer: a systematic review. Health Technol Assess 7 (2003) 1-157
5. Meltzer D. Can medical cost-effectiveness analysis identify the value of research?. In: Murphy K.M., and Topel R.H. (Eds). Measuring the gains from medical research: An economic approach (2003), University of Chicago Press, Chicago 206-247
6. Fowler Jr. F.J., Bin L., Collins M.M., et al. Prostate cancer screening and beliefs about treatment efficacy: A national survey of primary care physicians and urologists. Am J Med 104 (1998) 526-532
7. Fowler Jr. F.J., McNaughton-Collins M., Albertsen P.C., et al. Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer. JAMA 283 (2000) 3217-3222
8. Fleming C., Wasson J.H., Albertsen P.C., et al. A decision analysis of alternative treatment strategies for clinically localized prostate cancer. JAMA 269 (1993) 2650-2658
9. Rosen S. Hedonic prices and implicit markets: Product differentiation in pure competition. J Political Econ 82 (1974) 34-55
10. Cowen M.E., Miles B.J., Cahill D.F., et al. The danger of applying group-level utilities in decision analyses of the treatment of localized prostate cancer in individual patients. Med Decis Making 18 (1998) 376-380
11. Bennett C.L., Chapman G., Elstein A.S., et al. A comparison of perspectives on prostate cancer: Analysis of utility assessments of patients and physicians. Eur Urol 32 Suppl. 3 (1997) 86-88
12. Souchek J., Stacks J.R., Brody B., et al. A trial for comparing methods for eliciting treatment preferences from men with advanced prostate cancer: Results from the initial visit. Med Care 38 (2000) 1040-1050
13. Cantor S.B., Spann S.J., Volk R.J., et al. Prostate cancer screening: A decision analysis. J Fam Pract 41 (1995) 33-41
14. Albertsen P.C., Nease Jr. R.F., and Potosky A.L. Assessment of patient preferences among men with prostate cancer. J Urol 159 (1998) 158-163
15. Saigal C.S., Gornbein J., Nease R., et al. Predictors of utilities for health states in early stage prostate cancer. J Urol 166 (2001) 942-946
16. Stewart S.T., Lenert L., Bhatnagar V., et al. Utilities for prostate cancer health states in men aged 60 and older. Med Care 43 (2005) 347-355
17. Krahn M., Ritvo P., Irvine J., et al. Patient and community preferences for outcomes in prostate cancer: Implications for clinical policy. Med Care 41 (2003) 153-164
18. Kattan M.W., Cowen M.E., and Miles B.J. A decision analysis for treatment of clinically localized prostate cancer. J Gen Intern Med 12 (1997) 299-305
19. Holmberg L., Bill-Axelson A., Helgesen F., et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. New Engl J Med 347 (2002) 781-789
20. Steineck G., Helgesen F., Adolfsson J., et al. Quality of life after radical prostatectomy or watchful waiting. New Engl J Med 347 (2002) 790-796
21. Johansson J.E., Andren O., Andersson S.O., et al. Natural history of early, localized prostate cancer. JAMA 291 (2004) 2713-2719
22. Mantz C.A., Song P., Farhangi E., et al. Potency probability following conformal megavoltage radiotherapy using conventional doses for localized prostate cancer. Int J Radiat Oncol Biol Phys 37 (1997) 551-557
23. Zelefsky M.J., Leibel S.A., Gaudin P.B., et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 41 (1998) 491-500
24. Shipley W.U., Zietman A.L., Hanks G.E., et al. Treatment related sequelae following external beam radiation for prostate cancer: A review with an update in patients with stages T1 and T2 tumor. J Urol 152 (1994) 1799-1805
25. Hanks G.E., Schultheiss T.E., Hunt M.A., et al. Factors influencing incidence of acute grade 2 morbidity in conformal and standard radiation treatment of prostate cancer. Int J Radiat Oncol Biol Phys 31 (1995) 25-29
26. Incrocci L., Koper P.C., Hop W.C., et al. Sildenafil citrate (Viagra) and erectile dysfunction following external beam radiotherapy for prostate cancer: A randomized, double-blind, placebo-controlled, cross-over study. Int J Radiat Oncol Biol Phys 51 (2001) 1190-1195
27. Grimm P.D., Blasko J.C., Sylvester J.E., et al. 10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy. Int J Radiat Oncol Biol Phys 51 (2001) 31-40
28. Kleinberg L., Wallner K., Roy J., et al. Treatment-related symptoms during the first year following transperineal 125I prostate implantation. Int J Radiat Oncol Biol Phys 28 (1994) 985-990
29. Merrick G.S., Butler W.M., Dorsey A.T., et al. Rectal function following prostate brachytherapy. Int J Radiat Oncol Biol Phys 48 (2000) 667-674
30. Potters L., Torre T., Fearn P.A., et al. Potency after permanent prostate brachytherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 50 (2001) 1235-1242
31. Pound C.R., Partin A.W., Eisenberger M.A., et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281 (1999) 1591-1597
32. Fowler Jr. F.J., Barry M.J., Lu-Yao G., et al. Effect of radical prostatectomy for prostate cancer on patient quality of life: Results from a Medicare survey. Urology 45 (1995) 1007-1013
33. Talcott J.A., Rieker P., Propert K.J., et al. Patient-reported impotence and incontinence after nerve-sparing radical prostatectomy. J Natl Cancer Inst 89 (1997) 1117-1123
34. Quinlan D.M., Epstein J.I., Carter B.S., et al. Sexual function following radical prostatectomy: Influence of preservation of neurovascular bundles. J Urol 145 (1991) 998-1002
35. Gold M.R., Franks P., McCoy K.I., et al. Toward consistency in cost-utility analyses: Using national measures to create condition-specific values. Med Care 36 (1998) 778-792
36. Chapman G.B., Elstein A.S., Kuzel T.M., et al. A multi-attribute model of prostate cancer patient's preferences for health states. Qual Life Res 8 (1999) 171-180
37. Knight S.J., Nathan D.P., Siston A.K., et al. Pilot study of a utilities-based treatment decision intervention for prostate cancer patients. Clin Prostate Cancer 1 (2002) 105-114
38. Smith D.S., Krygiel J., Nease Jr. R.F., et al. Patient preferences for outcomes associated with surgical management of prostate cancer. J Urol 167 (2002) 2117-2122
39. Lubeck D.P., Grossfeld G.D., and Carroll P.R. A review of measurement of patient preferences for treatment outcomes after prostate cancer. Urology 60 3 Suppl. 1 (2002) 72-77
40. Meltzer D., Egleston B., and Abdalla I. Patterns of prostate cancer treatment by clinical stage and age. Am J Public Health 91 (2001) 126-128
41. Cooperberg M.R., Lubeck D.P., Meng M.V., et al. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol 22 (2004) 2141-2149
42. Impac Medical Systems. National Oncology Database. Available at: http://www.impac.com/products/oi/index.html. Accessed: August 28, 2007.
43. Chernichovsky D., and Zmora I. A hedonic prices approach to hospitalization costs. The case of Israel. J Health Econ 5 (1986) 179-191
44. Jang T.L., Bekelman J.E., Liu Y., et al. Visits to urologists and radiation oncologists prior to treatment decision making for clinically localized prostate cancer (LCaP). J Clin Oncol 25 18 Suppl. (2007) 323
45. de Groot V., Beckerman H., Lankhorst G., et al. How to measure comorbidity: A critical review of available methods. J Clin Epidemiol 56 (2003) 221-229
46. Jani A.B., Kao J., Heimann R., et al. Hormone therapy and radiotherapy for early prostate cancer: A utility-adjusted number needed to treat (NNT) analysis. Int J Radiat Oncol Biol Phys 61 (2005) 687-694
47. Ryan M., and Farrar S. Using conjoint analysis to elicit preferences for health care. BMJ 320 (2000) 1530-1533
48. Mazur D.J., Hickam D.H., and Mazur M.D. How patients' preferences for risk information influence treatment choice in a case of high risk and high therapeutic uncertainty: Asymptomatic localized prostate cancer. Med Decis Making 19 (1999) 394-398
49. Steginga S.K., and Occhipinti S. The application of the heuristic-systematic processing model to treatment decision making about prostate cancer. Med Decis Making 24 (2004) 573-583